WO1999038972A3 - Human genes and gene expression products ii - Google Patents

Human genes and gene expression products ii Download PDF

Info

Publication number
WO1999038972A3
WO1999038972A3 PCT/US1999/001619 US9901619W WO9938972A3 WO 1999038972 A3 WO1999038972 A3 WO 1999038972A3 US 9901619 W US9901619 W US 9901619W WO 9938972 A3 WO9938972 A3 WO 9938972A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
gene expression
expression products
human genes
polynucleotides
Prior art date
Application number
PCT/US1999/001619
Other languages
French (fr)
Other versions
WO1999038972A8 (en
WO1999038972A9 (en
WO1999038972A2 (en
Inventor
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Julie Sudduth-Klinger
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Birgit Stache-Crain
Original Assignee
Chiron Corp
Hyseq Inc
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Sudduth Klinger Julie
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Stache Crain Birgit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Hyseq Inc, Lewis T Williams, Jaime Escobedo, Michael A Innis, Pablo Dominguez Garcia, Sudduth Klinger Julie, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Stache Crain Birgit filed Critical Chiron Corp
Priority to US09/297,648 priority Critical patent/US6964868B1/en
Priority to EP99904288A priority patent/EP1053319A2/en
Priority to AU24716/99A priority patent/AU2471699A/en
Priority to JP2000556580A priority patent/JP2002519000A/en
Publication of WO1999038972A2 publication Critical patent/WO1999038972A2/en
Publication of WO1999038972A3 publication Critical patent/WO1999038972A3/en
Publication of WO1999038972A8 publication Critical patent/WO1999038972A8/en
Publication of WO1999038972A9 publication Critical patent/WO1999038972A9/en
Priority to US10/779,543 priority patent/US8101349B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
PCT/US1999/001619 1997-12-23 1999-01-28 Human genes and gene expression products ii WO1999038972A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US09/297,648 US6964868B1 (en) 1998-01-28 1999-01-28 Human genes and gene expression products II
EP99904288A EP1053319A2 (en) 1998-01-28 1999-01-28 Human genes and gene expression products ii
AU24716/99A AU2471699A (en) 1998-01-28 1999-01-28 Human genes and gene expression products ii
JP2000556580A JP2002519000A (en) 1998-01-28 1999-01-28 Human genes and gene expression products II
US10/779,543 US8101349B2 (en) 1997-12-23 2004-02-12 Gene products differentially expressed in cancerous cells and their methods of use II

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US7291098P 1998-01-28 1998-01-28
US7595498P 1998-02-24 1998-02-24
US8011498P 1998-03-31 1998-03-31
US8051598P 1998-04-03 1998-04-03
US8066698P 1998-04-03 1998-04-03
US10523498P 1998-10-21 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60/072,910 1998-10-28
US60/105,234 1998-10-28
US60/080,666 1998-10-28
US60/080,114 1998-10-28
US60/075,954 1998-10-28
US60/105,877 1998-10-28
US60/080,515 1998-10-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/779,543 Continuation-In-Part US8101349B2 (en) 1997-12-23 2004-02-12 Gene products differentially expressed in cancerous cells and their methods of use II

Publications (4)

Publication Number Publication Date
WO1999038972A2 WO1999038972A2 (en) 1999-08-05
WO1999038972A3 true WO1999038972A3 (en) 1999-12-23
WO1999038972A8 WO1999038972A8 (en) 2000-04-06
WO1999038972A9 WO1999038972A9 (en) 2001-05-17

Family

ID=27568324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001619 WO1999038972A2 (en) 1997-12-23 1999-01-28 Human genes and gene expression products ii

Country Status (3)

Country Link
EP (1) EP1053319A2 (en)
JP (1) JP2002519000A (en)
WO (1) WO1999038972A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066740A2 (en) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU4362199A (en) * 1998-05-18 1999-12-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteins and genes useful as tumor markers
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US6395877B1 (en) 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
WO2000000611A2 (en) * 1998-06-30 2000-01-06 Millennium Pharmaceuticals, Inc. 14273 receptor, a g-protein coupled receptor
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
WO2000008156A2 (en) * 1998-08-07 2000-02-17 Incyte Pharmaceuticals, Inc. Dna replication- and repair-associated proteins
AU2854600A (en) * 1999-01-25 2000-08-07 Zymogenetics Inc. Human polypeptide having multiple epidermal growth factor (egf) -like domains, zntr2
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2373191A1 (en) * 1999-05-14 2000-11-23 Incyte Genomics, Inc. Full-length molecules expressed in human tissues
AU5022200A (en) * 1999-05-19 2000-12-05 Human Genome Sciences, Inc. Tm4sf receptors
EP1124951A2 (en) * 1999-05-27 2001-08-22 Incyte Genomics, Inc. Human sorting nexins
FR2795414B1 (en) * 1999-06-22 2002-07-05 Ass Pour Le Dev De La Rech En POLYPEPTIDE ICBP90 AND ITS FRAGMENTS AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES AND APPLICATIONS TO THE DIAGNOSIS AND TREATMENT OF CANCER
DE19935303A1 (en) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonucleotides to inhibit the expression of human eg5
JP2003506042A (en) 1999-08-03 2003-02-18 ミレニアム ファーマシューティカルズ インク． Novel GPCR-like molecule 15571 of secretin-like family and use thereof
CA2385813A1 (en) 1999-09-24 2001-03-29 Lexicon Genetics Incorporated Human endothelin converting enzyme-like proteins and polynucleotides encoding the same
ES2189560B1 (en) 1999-10-01 2005-01-01 Consejo Superior De Investigaciones Cientificas DNA POLYMERASE K, NEW TUMOR MARKER.
US6518052B1 (en) * 1999-10-22 2003-02-11 Bristol-Myers Squibb Company Human homologue of yeast helicase and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6428980B1 (en) 1999-11-16 2002-08-06 Rigel Pharmaceuticals, Inc. Nucleic acids encoding RIP3 associated cell cycle proteins
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
ATE392474T1 (en) 2000-01-26 2008-05-15 Agensys Inc 84P2A9: PROSTATE AND TEST SPECIFIC PROTEIN EXHIBITING HIGH EXPRESSION IN PROSTATE CANCER
US6566502B1 (en) * 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US20020137675A1 (en) * 2000-02-08 2002-09-26 Taupier Raymond J. Polynucleotides and polypeptides encoded thereby
EP1259618A2 (en) * 2000-03-01 2002-11-27 Incyte Genomics, Inc. Human enzyme molecules
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
EP1297007A2 (en) * 2000-05-30 2003-04-02 Sugen, Inc. Mammalian protein phosphatases
EP1666497A3 (en) * 2000-06-02 2006-06-21 Genentech, Inc. Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer
ATE397094T1 (en) * 2000-06-15 2008-06-15 Novartis Vaccines & Diagnostic POLYNUCLEOTIDES FOR DETERMINING COLON CANCER
WO2002002761A2 (en) * 2000-06-30 2002-01-10 Millennium Pharmaceuticals, Inc. 57658, a human uridine kinase and uses thereof
FR2812305B1 (en) * 2000-07-28 2005-01-07 Commissariat Energie Atomique DNA MEMBER PROMOTING TRANSCRIPTION ACTIVITY, ACTIVE IN HUMAN CELLS AND GENERAL METHOD FOR ADJUSTING ACTIVITY
US7060456B2 (en) 2000-08-30 2006-06-13 Bayer Healthcare Ag Regulation of human protein phosphatase IIc-like enzyme
AU2002213084A1 (en) * 2000-10-11 2002-04-22 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
AU2001297741A1 (en) * 2000-11-22 2002-10-08 Diadexus, Inc. Compositions and methods relating to breast specific genes and proteins
WO2002046383A2 (en) * 2000-12-08 2002-06-13 Incyte Genomics, Inc. Protein modification and maintenance molecules
EP1239051A3 (en) * 2001-01-30 2004-03-17 Aeomica, Inc. Human posh-like protein 1
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
WO2002088349A1 (en) * 2001-04-27 2002-11-07 Genox Research, Inc. Method of examining allergic disease using cathepsin-c alternative splicing form as indication
AU2002327176A1 (en) * 2001-06-06 2002-12-16 Human Genome Sciences, Inc. 20 human secreted proteins
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
US20030120040A1 (en) 2001-06-29 2003-06-26 Genentech, Inc. Secreted and Transmembrane polypeptides and nucleic acids encoding the same
WO2003025214A1 (en) * 2001-09-14 2003-03-27 Medimolecular Pty. Ltd. Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
WO2003027276A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
EP2428571B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
EP1489180A1 (en) * 2002-03-07 2004-12-22 BF Research Institute, Inc. P18abeta rp gene and p18abeta rp protein, novel gene/protein (p60trp) interacting therewith to inhibit cell death and cell death promoter
JP2005527614A (en) 2002-05-29 2005-09-15 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング Pancreas-specific protein
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2003257631A1 (en) * 2002-08-21 2004-03-11 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
JP2009532038A (en) 2006-04-07 2009-09-10 バイオファルミカ リミテッド Transcription factor modulator
CN103757028B (en) * 2014-01-23 2015-09-09 南京医科大学 OSBPL2 mutated genes, its authentication method and detection kit

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALDI ET AL: "Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer", CLINICAL CANCER RESEARCH, vol. 2, no. 2, July 1996 (1996-07-01), pages 1239 - 1245 45, XP002099965 *
CARMECI ET AL: "Identification of a gene (GPR30) with homolgy to the G-protein -coupled receptor superfamily associated with estrogen receptor expression in breast cancer", GENOMICS, vol. 45, no. 3, 1 November 1997 (1997-11-01), pages 607 - 617 17, XP002099963 *
OKAMURA K ET AL: "Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin-6 in tumor necrosis factor-treated human microvascular endothelial cells", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 266, no. 29, 15 October 1991 (1991-10-15), pages 19162 - 19165, XP002108129 *
RADINSKY ET AL: "Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells", CLINICAL CANCER RESEARCH, vol. 1, no. 1, January 1995 (1995-01-01), pages 19 - 31 31, XP002099964 *
YEATMAN ET AL: "Identification of genetic alterations associated with the process of human experimental colon cancer liver metastasis in the nude mouse", CLINICAL & EXPERIMENTAL METASTASIS, vol. 14, no. 3, May 1996 (1996-05-01), pages 246 - 252 252, XP002099961 *
YEATMAN T ET AL: "Identification of a differentially-expressed message associated with colon cancer liver metastasis using an improved method of differential display", NUCLEIC ACIDS RESEARCH, vol. 23, no. 19, 1995, pages 4007 - 4008, XP002099962 *

Also Published As

Publication number Publication date
WO1999038972A8 (en) 2000-04-06
EP1053319A2 (en) 2000-11-22
WO1999038972A9 (en) 2001-05-17
WO1999038972A2 (en) 1999-08-05
JP2002519000A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
WO1999038972A9 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
WO1999033982A3 (en) Human genes and gene expression products i
WO2002014500A3 (en) Human genes and gene expression products
WO2001066753A3 (en) Human genes and gene expression products
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2000012702A3 (en) Human genes differentially expressed in colorectal cancer
WO2001064877A3 (en) Human schizophrenia gene
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2003050236A3 (en) Human genes and gene expression products isolated from human prostate
WO2000018916A3 (en) Human genes and gene expression products
WO2000073323A3 (en) Adam polynucleotides and polypeptides
WO2001072781A3 (en) Human genes and expression products
WO2001064876A3 (en) Human schizophrenia gene
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
WO2001014415A3 (en) Egfh2 genes and gene products
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09297648

Country of ref document: US

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/99 UNDER (30) ADD "60/105234 21.10.98 US 60/105877 20.10.98 US"

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 556580

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999904288

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999904288

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 131, 132, 591-594 AND 638-652, DESCRIPTION, REPLACED BY NEW PAGES 131, 132, 591-594 AND 638-652; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999904288

Country of ref document: EP